Stocks got off to a weak start Thursday as investors confronted data that showed inflation in September came in a bit hotter ...

An energy company has reverted from producing renewable fuels back to conventional production just weeks after filing for ...

Making a noteworthy insider sell on October 9, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX, is reported in the latest SEC filing.

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Vertex Energy Inc (VTNR) stock saw a decline, ending the day at $0.11 which represents a decrease of $-0.01 or -8.33% from the prior close of $0.12. The stock opened at $0.11 and touched a low of $0.1 ...

Vertex’s core cystic fibrosis portfolio remains its top/bottom-line driver, with elongated patent expiry for TRIKAFTA/KAFTRIO ...

October 9: Sold 48,957 shares at an average price of $41.31. After these sales, the trust retains ownership of approximately ...

Last year, the Food and Drug Administration (FDA) granted approval for CRISPR's gene therapy for sickle cell disease for ...

With an FDA decision looming over its first foray into the acute pain space, Vertex Pharmaceuticals has commissioned a pair ...

What Happened: Westphal's decision to sell 1,225,000 shares of Vertex was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Monday. The total value of the sale is $48,289 ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.39% higher to $455.31 Friday, on what proved to be an all-around ...